Literature DB >> 20433554

Higher levels of alanine aminotransferase within the reference range predict unhealthy metabolic phenotypes of obesity in normoglycemic first-degree relatives of patients with type 2 diabetes mellitus.

Olusegun A Mojiminiyi1, Nabila A Abdella, Hisham Al Mohammedi.   

Abstract

Obesity is a heterogeneous disorder with metabolically healthy and unhealthy phenotypes and varying degrees of cardiometabolic complications. To evaluate whether alanine aminotransferase (ALT) could be used for identification of obese phenotypes, the authors measured ALT, adiponectin, leptin, leptin receptor, free leptin index, high-sensitivity C-reactive protein, fasting insulin, glucose, and full lipid profile in 486 (176 men and 310 women) normoglycemic first-degree relatives of patients with type 2 diabetes mellitus with negative medication history and hepatitis screen. Patients were classified into obesity phenotypes on the basis of the degree of adiposity and the International Diabetes Federation criteria for the metabolic syndrome. One hundred and thirty-seven (28%) patients were positive for the metabolic syndrome, 32 (7%) had normal weight but metabolically unhealthy phenotype, and 201 (41%) were obese but metabolically healthy. ALT showed significant positive correlations with body mass index, waist circumference, beta-cell function, insulin, homeostasis model assessment for insulin resistance, high-sensitivity C-reactive protein, total cholesterol, and triglycerides and increased with increasing number of metabolic syndrome components. Binary logistic regression analyses showed that higher ALT levels within the normal range were significantly associated with the metabolic syndrome. ALT could be used for identification of the metabolically obese phenotype. Lowering the ALT upper normal reference limit will facilitate earlier detection of risky phenotypes of obesity.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20433554      PMCID: PMC8673014          DOI: 10.1111/j.1751-7176.2009.00238.x

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN: 1524-6175            Impact factor:   3.738


  22 in total

1.  The metabolic syndrome--a new worldwide definition.

Authors:  K George M M Alberti; Paul Zimmet; Jonathan Shaw
Journal:  Lancet       Date:  2005 Sep 24-30       Impact factor: 79.321

Review 2.  The metabolically obese, normal-weight individual revisited.

Authors:  N Ruderman; D Chisholm; X Pi-Sunyer; S Schneider
Journal:  Diabetes       Date:  1998-05       Impact factor: 9.461

3.  Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease.

Authors:  F Angelico; M Del Ben; R Conti; S Francioso; K Feole; S Fiorello; M G Cavallo; B Zalunardo; F Lirussi; C Alessandri; F Violi
Journal:  J Clin Endocrinol Metab       Date:  2004-12-14       Impact factor: 5.958

4.  Obesity: preventing and managing the global epidemic. Report of a WHO consultation.

Authors: 
Journal:  World Health Organ Tech Rep Ser       Date:  2000

5.  Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge.

Authors:  W T Friedewald; R I Levy; D S Fredrickson
Journal:  Clin Chem       Date:  1972-06       Impact factor: 8.327

6.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

7.  Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity.

Authors:  Jeffrey D Browning; Lidia S Szczepaniak; Robert Dobbins; Pamela Nuremberg; Jay D Horton; Jonathan C Cohen; Scott M Grundy; Helen H Hobbs
Journal:  Hepatology       Date:  2004-12       Impact factor: 17.425

8.  Relationship between unexplained elevations in alanine aminotransferase and serum leptin in U.S. adults: results from the Third National Health and Nutrition Examination Survey (NHANES III).

Authors:  Suthat Liangpunsakul; Naga Chalasani
Journal:  J Clin Gastroenterol       Date:  2004 Nov-Dec       Impact factor: 3.062

Review 9.  Molecular mediators of hepatic steatosis and liver injury.

Authors:  Jeffrey D Browning; Jay D Horton
Journal:  J Clin Invest       Date:  2004-07       Impact factor: 14.808

10.  Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity?

Authors:  Shivakumar Chitturi; Geoffrey Farrell; Linda Frost; Adamandia Kriketos; Rita Lin; Caroline Fung; Christopher Liddle; Dev Samarasinghe; Jacob George
Journal:  Hepatology       Date:  2002-08       Impact factor: 17.425

View more
  3 in total

1.  Altered expression of genes involved in lipid metabolism in obese subjects with unfavourable phenotype.

Authors:  V H Telle-Hansen; B Halvorsen; K T Dalen; I Narverud; N Wesseltoft-Rao; L Granlund; S M Ulven; K B Holven
Journal:  Genes Nutr       Date:  2013-01-08       Impact factor: 5.523

Review 2.  Obesity subtypes, related biomarkers & heterogeneity.

Authors:  Laura Perez-Campos Mayoral; Gabriel Mayoral Andrade; Eduardo Perez-Campos Mayoral; Teresa Hernandez Huerta; Socorro Pina Canseco; Francisco J Rodal Canales; Héctor Alejandro Cabrera-Fuentes; Margarito Martinez Cruz; Alma Dolores Pérez Santiago; Juan José Alpuche; Edgar Zenteno; Hector Martínez Ruíz; Ruth Martínez Cruz; Julia Hernandez Jeronimo; Eduardo Perez-Campos
Journal:  Indian J Med Res       Date:  2020-01       Impact factor: 2.375

3.  Effect of chicory seed extract on glucose tolerance test (GTT) and metabolic profile in early and late stage diabetic rats.

Authors:  Abdolreza Ghamarian; Mohammad Abdollahi; Xiaogang Su; Azita Amiri; Ali Ahadi; Azin Nowrouzi
Journal:  Daru       Date:  2012-10-15       Impact factor: 3.117

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.